Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) was downgraded by analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Sunday, Wall Street Zen reports.
Separately, Weiss Ratings cut shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, November 12th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Hillstream Biopharma has a consensus rating of “Sell”.
Read Our Latest Research Report on Hillstream Biopharma
Hillstream Biopharma Trading Down 1.6%
Hillstream Biopharma (NASDAQ:CNTN – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.16) earnings per share (EPS) for the quarter. The firm had revenue of $3.05 million for the quarter.
About Hillstream Biopharma
Hillstream BioPharma is a biotechnology company focused on developing experimental treatments for cancer, particularly drug-resistant tumors and cancer stem cells. Its research centers on ferroptosis, a form of cell death that may offer a way to attack cancer cells that are difficult to treat with existing therapies. The company’s development work includes its LION platform, which uses liposomal iron oxide nanoparticles to deliver iron to cancer cells and promote ferroptosis. Hillstream has described HSB-1216 as a potential cancer treatment based on this approach.
See Also
- Five stocks we like better than Hillstream Biopharma
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Hillstream Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
